| What is the value for money of medicines? A registry study. | |
| | |
MedLine Citation:
|
PMID: 21812796 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
What is known and Objective: Economic evaluation is used to assess the value for money of medicines and inform pharmaceutical pricing/reimbursement decisions in many countries. This paper aims to report on estimates of the value for money of medicines in Europe. Methods: Estimated cost-utilities were derived from studies included in the Tufts Medical Center Cost-Effectiveness Analysis Registry between 2000 and 2007. For each study, the following variables were examined: publication year, target population, intervention type, country of patient sample, disease classification, prevention stage, funding source, study perspective, discounting, sensitivity analysis, incremental cost-utility ratio (ICUR) and methodological quality. Results and Discussion: Six hundred and eight ICURs were reported in 231 cost-utility analyses. Around 17·1% of ratios related to medicines that were more effective and less expensive than the comparator; 76·5% related to medicines that improved outcomes, but increased costs; and 6·4% related to medicines that were less effective and more expensive than the comparator. The median ratio was 12 238 € per quality-adjusted life year (QALY). Using threshold values of 20 000 and 50 000 € per QALY, the probability that medicines provided value for money was 58% and 81%, respectively. Preventive medicines studied provided more value for money than curative medicines (P = 0·002). Studies sponsored by industry generated more favourable results than studies sponsored from other sources (P < 0·001). However, no association was observed between the funding source and the methodological quality of economic evaluations. What is new and Conclusion: The evidence base suggests that the majority of medicines provided value for money. Such information informs policy decisions relating to the allocation of scarce health care resources in Europe. |
| | |
Authors:
|
S Simoens |
Related Documents
:
|
17928896 - Management of dairy heifers and its relationships with the incidence of clinical mastitis. 15745196 - Academic clinical research in the new regulatory environment. 22071276 - Why should we bother with assessment moderation? 22032566 - Assuring quality in point-of-care testing: evolution of technologies, informatics, and ... 1400076 - Leeches to hirulogs and other thrombin-directed antithrombotics. 16678336 - An inexact two-stage mixed integer linear programming method for solid waste management... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-8-4 |
Journal Detail:
|
Title: Journal of clinical pharmacy and therapeutics Volume: - ISSN: 1365-2710 ISO Abbreviation: - Publication Date: 2011 Aug |
Date Detail:
|
Created Date: 2011-8-4 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8704308 Medline TA: J Clin Pharm Ther Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
© 2011 Blackwell Publishing Ltd. |
Affiliation:
|
Research Centre for Pharmaceutical Care and Pharmaco-economics, Katholieke Universiteit Leuven, Leuven, Belgium. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Comparison of media formulations used to selectively cultivate Dekkera/Brettanomyces.
Next Document: Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patient...